- Joined
- Aug 9, 2001
- Messages
- 3,757
- Reaction score
- 7
Whats the prognosis in terms of % survival for 1, 5, 10 years?
Cant find any info on this.
Cant find any info on this.
Chemotherapy is usually the first treatment recommended for multiple myeloma. In most individuals, chemotherapy partially controls multiple myeloma; rarely, chemotherapy leads to complete remission. The response to initial chemotherapy also helps to estimate how long an individual will survive.
A definition of a response to chemotherapy refers to a 50 percent reduction in blood and urine levels of the abnormal M protein and an improvement of symptoms. Individuals who have any response to chemotherapy (even if it does not meet the above definition) survive, on average, 43 months, while individuals who do not have a response survive, on average, 19 months.
Between 50 and 60 percent of individuals with multiple myeloma have a response to melphalan-prednisone chemotherapy. The average survival among individuals treated with this chemotherapy is three years.
TRANSPLANTATION ?
Transplantation, when successful, prolongs survival, can lead to a remission, and, in rare cases, may cure multiple myeloma. However, transplantation has several problems. The high-dose chemotherapy (even with radiation) given before transplantation may fail to kill all of these cells, allowing the condition to relapse. Such treatment also puts the patient at risk for serious infections and bleeding, which might be fatal.
Effectiveness of transplantation ? About 7 percent of individuals die from complications related to transplantation. However, compared with chemotherapy, autologous bone marrow transplantation is more likely to produce a response and a complete remission, and is associated with survival approximately 12 months longer than that produced by chemotherapy alone.
Single versus double autologous transplantation ? Some studies suggest that double autologous transplantation (two consecutive autologous transplantations) may be more effective than single autologous transplantation for treating multiple myeloma. The second transplantation is usually performed within six months of the first.
Among individuals undergoing double transplantation, 51 percent have a complete remission, and the remission lasts, on average, 50 months. One study has shown that double transplantation improves long-term survival relative to single transplantation.
Interferon therapy after autologous transplantation ? Interferon therapy after autologous transplantation may be recommended for some individuals. Studies suggest that in individuals undergoing autologous bone marrow transplantation, interferon therapy delays the onset of a relapse and leads to better survival in the short term.
Allogeneic bone marrow transplantation ? An allogeneic stem cell or bone marrow transplantation is a treatment option for only 5 to 10 percent of individuals with multiple myeloma. This type of transplantation has two advantages over autologous transplantation: the donated stem cells do not contain any malignant plasma cells, and the transplanted cells may target and help control any remaining myeloma cells. This latter beneficial effect is called the "graft versus tumor" effect. However, allogeneic transplantation is also associated with a "graft versus host" effect, in which cells from the donor may attack tissues of the host, resulting in damage to various organs, such as the skin, liver, and intestines.
Allogeneic transplantation requires bone marrow or stem cells from a donor with a matching tissue type. Under the best conditions, a sibling may qualify as a donor; otherwise national bone marrow donor banks may be employed to find a donor with a matching tissue type. The donated bone marrow or stem cells are given to the patient after he/she receives appropriate doses of high-dose chemotherapy and radiation to reduce the number of malignant plasma cells.
Up to 52 percent of individuals have a complete response after allogeneic transplantation. Thirty percent of individuals live for at least four years, and 20 percent of individuals live for at least 10 years. The likelihood of a complete response to allogeneic bone marrow transplantation is highest in individuals with a lower number of myeloma cells and in individuals who have had a complete response to the initial chemotherapy.
Although multiple myeloma usually relapses after allogeneic transplantation, some individuals are cured of multiple myeloma after this type of transplantation.
Unfortunately, approximately 25 percent of individuals who undergo allogeneic transplantation die from transplant-related complications, such as infection, lung inflammation, and graft-versus-host disease. Thus, the potential benefit of allogeneic transplantation (long-term disease control or cure) must be weighed against the potential for immediate morbidity and mortality.
Donor lymphocyte infusion ? Donor lymphocyte infusion is currently an experimental procedure. This procedure is an option for individuals who have a relapse of multiple myeloma after allogeneic bone marrow transplantation. During this procedure, lymphocytes collected from the original donor are given to the individual; these lymphocytes target the myeloma cells and may produce a beneficial "graft versus tumor" effect. Fifty-two percent of individuals have a response to this procedure, and 22 percent of individuals have a complete response.
Syngeneic transplantation ? A syngeneic transplantation refers to a transplantation between identical twins. For individuals who have an identical twin, this treatment option is more effective than either autologous or allogeneic transplantation. The average survival without a progression of multiple myeloma is 72 months.
Other transplantation programs ? Because autologous transplantation is not often curative and allogeneic transplantation carries a high mortality, other solutions have been sought. These include "mini transplants" (also called nonmyeloablative transplants) in which the patient receives a lower dose of chemotherapy prior to an allogeneic transplant. Another strategy, which is currently being evaluated, is a tandem transplant in which the patient first receives the less toxic autologous transplant followed by an allogeneic transplant at a time when the patient is more able to tolerate this procedure.
Remission after transplantation ? The strict definition of remission requires that there are no signs or symptoms of multiple myeloma and that highly sensitive tests do not detect any abnormal plasma cells. This type of remission occurs in about 4 percent of individuals after autologous transplantation and about 19 percent of individuals after allogeneic transplantation.
Its from UptoDate. I didn't want to say that because I was worried about copyright infringement. The numbers are different depending on were you look.Adawaal said:I would agree with most of what Mustafa posted. [Not sure where that was "drudged up," but probably best to cite the reference when quoting it en bloc like that....] .
MacGyver...noone here gives a $hit about what you think is valid data.Macgyver said:I prefer not to use the terms "partial" or "complete" response because they are basically worhtless parameters from a patients point of view.
What about some of the newer procedures? does anybody have survival/remission data on that? Again, I dont care about partial/complete response rates, just overall remission/survival data.
MustafaMond said:MacGyver...noone here gives a $hit about what you think is valid data.
You are a pretty dense, and I don't know why I would think you had changed, and that I could help you learn.
You've got a lot to learn about cancer, if you think you can just find a sheet of numbers and start throwing around mortality data.
And by the way...Who cares what you "prefer" to tell the patient? You are no more intelligent than one, and don't assume that patients are so dumb that they can't understand things like plasma cell counts.
I don't appreciate you demanding tone
Do you think this a carry-out research kiosk?
This is not a McDonald's where you can just order a cheeseburger and drive away.
Do your own damn research, and knock yourself out, tool.